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INTRODUCTION
Breast cancer screening focuses on detecting occult 
cancer in its early stages without lymph node metastasis 
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square or Fisher’s exact test and continuous variables were compared using the independent t test or Mann-Whitney U test.
Results: In 1451 women, 19 cancers (1.3%) were detected; two (0.1%) were diagnosed at 6 months and 17 (1.2%) were 
diagnosed after 12.3 months. The malignancy rates were both 1.3% in the screening (9 of 699) and tertiary (10 of 752) centers. 
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were ductal carcinomas in situ and eight were invasive cancers. Two of the invasive cancers were diagnosed at 6 months and 
the remaining eight cancers newly developed after 13.1 months.
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and distant spread (1). Although mammography is the 
only screening method proven to reduce mortality so far, 
its sensitivity varies, ranging 80–98% in women with 
fatty breast tissue to 30–48% in women with dense breast 
tissue (2, 3). Breast ultrasonography (US) is an attractive 
supplemental screening tool in women with dense breast 
tissue and the addition of US to screening mammography 
increases cancer detection yield by 1.9 to 6.8 cancers 
per 1000 women (2, 4-12). However, adding screening 
US results in increased cost, increased false-positive US 
examination findings, and higher benign biopsy rates (13-
16). One reason for false-positive US results is the category 
3 assessment of the American College of Radiology (ACR) 
Breast Imaging Reporting and Data System (BI-RADS) 
(17). The BI-RADS 3 assessment comprises 14.6–41.4% of 
all screening US (11, 15, 16, 18-21). However, the overall 
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malignancy rate of BI-RADS 3 lesions is low, ranging from 
0.2% to 1.7% (11, 15, 16, 18, 22, 23). Cancers initially 
assessed as BI-RADS 3 and detected during follow-up are 
still in the early stage of malignancy while being small in 
size, ranging from 2 mm to 18 mm in size (11, 15, 16, 18, 
22, 23). Most cases in past studies have had no axillary 
lymph node metastasis (11, 15, 16, 18, 22). Therefore, 
previous reports suggested one-year follow-up for women 
with BI-RADS 3 lesions on screening US (11, 16, 21, 22), 
and criteria to downgrade the initial BI-RADS category 3 
assessment to category 2 (24). 
In tertiary referral centers, screening breast US is 
performed for asymptomatic women with negative or 
benign findings on their screening mammogram. Community 
hospitals and private clinics selectively refer women to 
tertiary centers for screening US. Asymptomatic women with 
gynecological malignancies, including ovarian cancer, or 
receiving hormonal replacement therapy undergo screening 
US at tertiary centers. The characteristics of women who 
undergo screening US at screening centers may be different 
from those of women screened at tertiary centers. To our 
knowledge, no study has compared follow-up intervals 
and follow-up results in women with BI-RADS 3 lesions on 
screening US between screening and tertiary centers. 
Therefore, we aimed to assess the appropriate follow-
up interval, and rate and timepoint of cancer detection in 
women with BI-RADS 3 lesions on screening US according 
to the type of institution. 
MATERIALS AND METHODS
The Institutional Review Board approved this 
retrospective study and required neither patient approval 
nor informed consent for our review of patient images and 
medical records.
Study Population
In our institution, the screening center is a separate 
facility and at a separate site from the main institution 
which is a tertiary center. From March 2013 to February 
2015, 4776 screening US examinations were performed in 
the screening center and 1118 women (23.4%) without 
prior breast cancer surgery were initially assessed as BI-
RADS 3. Among them, 349 women without at least 6 months 
of follow-up and 70 women with probably benign lesions on 
screening mammogram and/or additional mammogram were 
excluded. A total of 699 women with negative or benign 
mammogram findings (n = 664) or without mammogram 
examinations (n = 35) were included in our study. 
In the tertiary center, the purpose of the US examination 
was recorded on the radiologic report. Screening US was 
defined as US examinations performed for asymptomatic 
women with negative or benign assessment of screening 
mammograms at outside hospitals or who did not undergo 
mammography, asymptomatic women with negative or 
benign assessment on previous US and mammography at 
our institution, or asymptomatic women with gynecological 
disease or receiving hormonal replacement therapy with 
negative or benign screening mammograms. Breast US 
examinations performed on women who had undergone 
prior breast cancer surgery were not defined as screening 
US. Among 43950 US examinations performed in the 
tertiary center, 8846 US examinations were performed 
in the screening setting. Of 828 women with BI-RADS 3 
assessment on screening US (9.4%), 52 women without at 
least 6 months of follow-up and 24 with probably benign 
lesions on mammograms were excluded. Finally, 752 women 
with negative or benign mammogram results (n = 663) or 
who did not undergo mammographic examination (n = 89) 
were included in our study. 
Mammographic and US Examinations
In the screening center, screening US examinations and 
mammogram interpretations were performed by five board-
certified radiologists with 3 to 7 years of experiences in 
breast imaging. Two of the radiologists had completed one 
year of fellowship training for breast imaging while the 
other three had only completed their residency training. 
Mammograms were obtained using dedicated equipment for 
digital mammography (Lorad Selenia, Hologic, Danbury, CT, 
USA). Mammography was usually performed on the same day 
as the screening US. US examinations were performed using 
high-resolution US equipment (iU22, Phillips-Advanced 
Technology Laboratories, Bothell, WA, USA) with a 5–12-MHz 
linear array transducer. 
In the tertiary center, screening US examination and 
mammogram interpretation were performed by 11 board-
certified radiologists dedicated to breast imaging with 1 
to 20 years of experience in breast imaging. Mammograms 
were obtained using dedicated equipment for digital 
mammography (Senographe DS, GE Healthcare, Milwaukee, 
WI, USA; Lorad Selenia) and digital tomosynthesis 
(Selenia Dimensions, Hologic). In the screening setting, 
only 2-dimensional mammograms were obtained, with no 
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tomosynthesis. High-resolution US equipment (iU22; LOGIQ 
9, GE Healthcare) and 5–12- or 7–12-MHz linear array 
transducers were used. Mammograms and US examinations 
were originally reported according to the ACR BI-RADS in 
both centers (17). 
In both the tertiary and screening centers, standard 
mediolateral oblique and craniocaudal views were obtained. 
Additional views were obtained when needed. For this study, 
an available mammogram was defined as a mammogram 
obtained 6 months before or after the screening US. 
Screening US included bilateral whole breasts and the 
axillae. Lesions were assessed as category 3 on US based 
on the following features: an oval circumscribed bordered 
mass parallel to the skin and no or minimal posterior 
enhancement, a hyperechoic mass with central hypo- or 
anechogenity suggesting fat necrosis, a hypoechoic mass 
with a homogeneous low-level internal echo, and a clustered 
microcyst (13, 16, 17). Orthogonal images with and without 
calipers were documented for all lesions detected on US, 
and Doppler US was used for lesion characterization. After 
6 months, follow-up breast US was performed. If cancer was 
diagnosed at this time, mammography or tomosynthesis 
was additionally performed. At 12 months, both follow-up 
US and mammography were performed. Follow-up breast US 
at 6 and 12 months included bilateral whole breasts and 
axillae.
In both centers, the radiologists or clinicians checked 
each patient’s family history of breast cancer and history of 
hormone replacement therapy and wrote in the radiologic 
reports or electronic medical records. We reviewed both for 
all patients included in this study.
Data and Statistical Analysis
Age, prevalence or incidence screening US, family history 
of breast cancer, hormone replacement therapy, malignancy 
rate, and follow-up interval from the date of initial BI-
RADS 3 assessment to the date of last follow-up or cancer 
detection, and pathological characteristics of the detected 
cancers were compared between the two centers. For 
cancer cases, we classified detection intervals into two 
categories; “at 6 months,” which included cancers detected 
6–9 months after initial BI-RADS 3 assessment, and “after 
12 months,” which included cancers detected after 12 
months. Women were subclassified and analyzed according 
to their mammographic breast density (fatty and dense 
mammography density) and whether they were 40 years 
or older. Of 1451 women, 124 did not have a mammogram 
available and were included in the dense mammographic 
density subgroup because 95 of the 124 women were 
younger than 40 years old. Nominal variables were 
compared using the chi-square or Fisher’s exact test and 
continuous variables were compared using the independent 
t test or Mann-Whitney U test. Statistical analyses were 
performed using SPSS (version 23.0, IBM Corp., Armonk, 
NY, USA) software. A two-sided p < 0.05 was considered to 
indicate statistical significance.
RESULTS
Mean age and mammographic density were not 
significantly different between the two centers (p = 0.281 
and 0.223, respectively) (Table 1). The mean follow-
up interval from the initial assessment to last contact or 
cancer diagnosis was longer in the tertiary center than in 
the screening center (p < 0.001). Prevalence screening US 
(76.7%, 536 of 699) was more frequently performed in the 
screening center than in the tertiary center (44.4%, 334 of 
752) (p < 0.001). In the tertiary center, 72 women (9.6%) 
had a family history of breast cancer; in the screening 
center, 29 women (4.1%) had a family history of breast 
cancer (p < 0.001). In the tertiary center, 140 (18.6%) of 
752 women underwent hormone replacement therapy, while 
in the screening center, 37 (5.3%) of 699 women underwent 
hormone replacement therapy (p < 0.001). 
Of 1451 women, 19 cancers (1.3%) in 19 women were 
diagnosed during follow-up. Seventeen cancers were 
invasive and two cancers were in situ. Three cancers (0.2%) 
were BI-RADS 3 lesions progressing at 7.7, 12.4, and 21.2 
months, and 16 cancers (1.1%) newly developed. Only two 
cancers (0.1%) were diagnosed at 6 months and 17 (1.2%) 
were diagnosed after 12 months. Nine cancers (1.3% of 
699) were diagnosed at the screening center and 10 (1.3% 
of 752) at the tertiary center. The malignancy rates did not 
differ between the two centers (p > 0.999). Six cancers 
from the screening center were detected on prevalence US 
and eight cancers from the tertiary center were detected on 
incidence US, which was not significantly different between 
centers (p = 0.070). 
When a cut-off age of 40 years was applied, the mean 
follow-up interval to last contact or cancer diagnosis was 
longer in the tertiary center (33.3 ± 11.4 months, p = 0.001) 
for 1138 women 40 years or older (Table 2). Of 1356 women 
with dense mammography density, the mean follow-up 




tertiary center (33.5 ± 11.3 months, p < 0.001) (Table 3).
The characteristics of the 19 cancers, including one case 
with axillary lymph node metastasis (5.3%, 1 of 19), are 
listed in Table 4. Median age, cancer diagnosis according 
to the cut-off age of 40 years, mean interval to cancer 
diagnosis, and diagnosis at 6 months or after 12 months 
Table 1. Comparisons of Clinic-Pathological Characteristics between Screening and Tertiary Center
Characteristics Screening Center (n = 699) Tertiary Referral Center (n = 752) P
Mean age (years, SD) 47.4 ± 9.3 47.9 ± 9.7 0.281
Mean follow-up interval* (months, SD)   30.9 ± 11.2   33.2 ± 11.5 < 0.001
Mammographic density (%) 0.223
Grade A and B (n = 95) 52 (7.4) 43 (5.7)
Grade C and D (n = 1356) 647 (92.6) 709 (94.3)
US screening (%) < 0.001
Prevalence (n = 870) 536 (76.7) 334 (44.4)
Incidence (n = 581) 163 (23.3) 418 (55.6)
Family history (%) < 0.001
Yes 29 (4.1) 72 (9.6)
No 670 (95.9) 680 (90.4)
Hormone replacement therapy (%) < 0.001
Yes 37 (5.3) 140 (18.6)
No 662 (94.7) 612 (84.1)
Cancer detection rate during follow-up (n = 19) (%) 9 (1.3) 10 (1.3) > 0.999
Cancer detection interval (%) 0.500
At 6 months (n = 2) 0 (0) 2 (0.3)
After 12 months (n = 17) 9 (1.3) 8 (1.1)
Cancer detection rate according to US screening (%) 0.070
Prevalence 6 (0.9) 2 (0.3)
Incidence 3 (0.4) 8 (1.1)
*Follow-up to last contact or cancer diagnosis. SD = standard deviation, US = ultrasonography
Table 2. Comparisons of Clinic-Pathological Characteristics according to Cut-Off Age of 40 Years
Characteristics
Less than 40 Years (n = 313)
Characteristics

















Mean age (years, SD) 34.8 ± 3.7 34.0 ± 4.3 0.093 Mean age (years, SD) 51.2 ± 6.9 51.4 ± 7.2 0.486
Mean follow-up interval* 
  (months, SD)
30.5 ± 10.5 32.8 ± 11.7 0.074
Mean follow-up interval*
  (months, SD)
31.0 ± 11.4 33.3 ± 11.4 0.001
Mammographic density (%) > 0.999 Grade on mammogram (%) 0.190
Grade A and B (n = 5) 3 (1.9) 2 (1.3) Grade A and B (n = 90) 49 (9.1) 41 (6.8)
Grade C and D (n = 308) 158 (98.1) 150 (98.7) Grade C and D (n = 1048) 489 (90.9) 559 (93.2)
Cancer detection rate 
  during follow-up (n = 2) (%)
2 (1.2) 0 (0) 0.499 Malignancy rate (n = 17) (%) 7 (1.3) 10 (1.7) 0.793
*Follow-up to last contact or cancer diagnosis.
Table 3. Comparisons of Clinic-Pathological Characteristics according to Breast Density
Characteristics
Fatty Breast (n = 95) Dense Breast (n = 1356)
Screening 
Center (n = 52)
Tertiary Referral 
Center (n = 43)
P
Screening 
Center (n = 647)
Tertiary Referral 
Center (n = 709)
P
Mean age (years, SD) 54.3 ± 9.2 54.9 ± 7.4 0.731 46.8 ± 9.1 47.5 ± 9.6 0.189
Mean follow-up interval* (months, SD) 34.0 ± 11.9 32.4 ± 13.0 0.551 30.8 ± 11.1 33.5 ± 11.3 < 0.001
Cancer detection rate during follow-up (%) 1 (2.3) 0 (0) 0.453 9 (1.4) 98 (1.3) > 0.999
*Follow-up to last contact or cancer diagnosis.
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were not significantly different between the two centers (all 
p > 0.05) (Table 5). All nine cancers found in the screening 
center were invasive, a median 9 mm (range, 2–12 mm) in 
size, without lymph node metastasis and diagnosed after 
12.3 months. No cancers were found at 6 months in the 
screening center. Even though two cancers in the screening 
center showed progression at 12.4 months and 21.2 
months, they were invasive cancers 9 mm and 12 mm in 
size without lymph node metastasis. In the tertiary center, 
eight were invasive cancers and two were ductal carcinomas 

















Features of Cancer Detection
1 57 12.3 None S IDC   9 0 
New
Non-visible on MG
2 59 12.4 Palpable S
Metaplastic 
  carcinoma
  9 0
Increased size (4 mm to 14 mm)
Mass on MG
3 49 21.2 Palpable S IDC 12* Unknown
Increased size (10 mm to 12 mm)
Mass on MG
4 46 26.1 None S IDC 12 0 
New
Non-visible on MG
5 37 28.5 
Bloody nipple 
  discharge
S IDC   2 0 
New
Non-visible on tomosynthesis
6 37 31.8 None S IDC   8* Unknown
New
Non-visible on MG
7 49 33.1 Palpable S IDC   7 0 
New
Mass on MG
8 60 35.9 Palpable S IDC 11 0 
New
Mass on MG
9 40 36.9 Palpable S IDC   7 0 
New
Non-visible on MG
10 44 6.8 None T IDC 16 1 
New
Mass on MG
11 68 7.7 None T IDC   7 0 
Increased size (5 mm to 7 mm)
Non-visible on MG
12 55 13.1 None T ILC 10 0 
New
Non-visible on MG
13 47 16.5 None T DCIS 24 0 
New
Non-visible on MG
14 61 18.2 None T IDC 22 0 
New
Microcalcifications on MG
15 53 20.6 None T DCIS 10 0 
New
Mass on MG
16 43 25.3 None T IDC   4 0 
New
Microcalcifications on MG
17 47 35.1 None T IDC   7* Unknown
New
Non-visible on MG
18 49 37.8 None T IDC   6 0 
New
Mass on MG
19 56 38.3 None T IDC 13 0 
New
Mass on MG
*Surgery was not performed at outside institution and size on US at time of cancer diagnosis was described. DCIS = ductal carcinoma in 
situ, IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma, MG = mammography, New = newly developed suspicious lesion on 




in situ. Two cancers (0.3%, 2 of 752) in the tertiary center 
were diagnosed at 6.8 months and 7.7 months; one showing 
progression at 7.7 months was a 7-mm invasive cancer 
without lymph node metastasis (Fig. 1) and the other newly 
developing at 6.8 months was a 16-mm invasive cancer with 
one axillary lymph node metastasis (Fig. 2). The other eight 
cancers were newly developing cancers diagnosed after 
13.1 months; six invasive cancers were 4 mm to 22 mm in 
size without lymph node metastasis and two were in situ 
cancers. At the time of cancer diagnosis, symptoms such as 
palpable lumps (n = 5) and bloody nipple discharge (n = 1) 
were more frequently present in the screening center (66.7% 
of 9 cancers) than in the tertiary center (0% of 10 cancers) 
(p = 0.003). Of the 19 women with cancer, 16 underwent 
surgery at our institution. Tumor size on pathology, T stage, 
and N stage were not significantly different between the 
two centers (all p > 0.05). 
DISCUSSION
In our study, the malignancy rates in women with the 
BI-RADS 3 assessment on screening US were both 1.3% 
in the screening and tertiary centers, which was less than 
the 2% of the recommended range (17) and comparable 
with previous studies (10, 11, 15-18, 22). Two cancers 
(0.1%) were diagnosed at 6 months; one progressed from 
a BI-RADS 3 lesion and the other was a new cancer. The 
remaining 17 (1.2%) were diagnosed after 12.3 months. At 
6 months, the malignancy rates were 0% in the screening 
center and 0.3% in the tertiary center. Three cancers (0.2%) 
progressed from BI-RADS 3 lesions at 7.7, 12.4, and 21.2 
months while the other 16 (1.1%) were newly developed 
cancers. 
For BI-RADS 3 lesions on screening mammograms, 
such as non-calcified solid masses with round or oval 
Table 5. Characteristics of Detected Cancers
Characteristics Screening Center (n = 9) Tertiary Referral Center (n = 10) P
Median age (years, range) 49 (37–60) 51 (43–68) 0.400
Women 40 years or older (n = 17) (%) 7 (77.8) 10 (100) 0.211
Women less than 40 years (n = 2) (%) 2 (22.2) 0 (0)
Median interval of cancer detection (months, range) 28.5 (12.3–36.9) 19.4 (6.8–38.3) 0.179
Cancer detection interval 0.474
At 6 months (n = 2) (%) 0 (0) 2 (20.0)
After 12 months (n = 18) (%) 9 (100) 8 (80.0)
Mammographic density (%) > 0.999
Grade A and B (n = 1) 0 (0) 1 (10.0)
Grade C and D (n = 18) 9 (100) 9 (90.0)
Interval change of detected cancers (%) 0.582
Newly developed lesions (n = 16) 7 (77.8) 9 (90.0)
Increased size of existing lesions (n = 3) 2 (22.2) 1 (10.0)
Cancer type (%) 0.474
In situ cancer (DCIS) (n = 2) 0 (0) 2 (20.0)
Invasive caner (n = 17) 9 (100) 8 (80.0)
Symptom at cancer diagnosis (%) 0.003
Bloody nipple discharge (n = 1) 1 (11.1) 0 (0)
Palpable lump (n = 5) 5 (55.6) 0 (0)
Negative (n = 13) 3 (33.3) 10 (100)
Pathology (n = 16)* (n = 7) (n = 9)
Median invasive tumor size (mm) 9 (2–12) 10 (4–22) 0.535
T stage (%) 0.475
0 (n = 2) 0 (0) 2 (22.2)
T1 (n = 13) 7 (100) 6 (66.7)
T2 (n = 1) 0 (0) 1 (11.1)
N stage (%) > 0.999
0 (n = 7) 7 (100) 8 (88.9)
1 (n = 1) 0 (0) 1 (11.1)
*Of 19 women with cancers, 16 underwent surgery in our institution.
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shape, a solitary group of round microcalcifications, or 
focal asymmetry without associated calcifications (25-
29), a 6-month follow-up is recommended due to the low 
malignancy rate, detection of mostly early-stage cancers 
after 6 months, and cost reduction with immediate biopsy 
(17, 25, 27, 30). Similar strategies are applied to BI-RADS 
3 lesions identified on screening US (17). However, the 
effectiveness of a 6-months follow-up US is questionable 
(15, 16, 21, 22). Furthermore, the very low malignancy 
rates of 0.2% to 1.0% (11, 15, 16, 18, 21-23) and high 
Fig. 1. 68-year-old women with benign calcifications on screening mammogram and BI-RADS category 3 lesion on screening US 
performed at tertiary center. 
A. Initial transverse. B. Initial longitudinal scan. Initially, 5-mm-sized lesion was assessed as BI-RADS category 3. C. Follow-up transverse. 
D. Follow-up longitudinal scan. At 7.7 months of follow-up, lesion progressed to 7 mm in size with suspicious features. This change was not 
detected on mammogram at 7.7 months. It was 7-mm-sized triple-negative invasive ductal carcinoma with nuclear grade 2 and without axillary 





Fig. 2. 48-year-old woman had benign findings on screening mammogram and BI-RADS category 3 lesions on screening US 
performed at tertiary center. 
A. Screening mammogram. B. Follow-up mammogram. C. Follow-up US. All BI-RADS 3 lesions showed no change on follow-up US at 6.8 months. 
However, new 14-mm-sized BI-RADS category 4C lesion was detected on both US and mammogram (arrow). It was 16-mm-sized luminal A type 





false-positive rates of US examinations during follow-up are 
problematic. A previous study found newly developed BI-
RADS 3 lesions in 26.4%, 23.6%, and 24.6% of all cases in 
year 1, 2, and 3, respectively, despite the low malignancy 
rate (16). Prior reports recommended one year of follow-
up for multiple bilateral circumscribed masses or BI-RADS 
3 lesions on screening US (22, 31). Of 1451 women, only 
three cancers (0.2%) progressed from BI-RADS 3 lesions 
at 7.7, 12.4, and 21.2 months. In our screening center, 
the malignancy rate was 1.3% and all malignancies were 
diagnosed after 12.3 months. Therefore, a one-year follow-
up might be recommended in the screening center. In the 
tertiary centers, two malignancies (0.3%) were diagnosed at 
the 6-month follow-up; therefore, more caution is needed 
in tertiary centers and a 6-month follow-up may remain 
appropriate. 
Most cancers in previous studies diagnosed after initial 
BI-RADS 3 assessment on screening US were T1 stage 
(range, 2–18 mm) (11, 15, 16, 18, 22, 23) without lymph 
node metastasis (11, 15, 18, 22). In our screening center, 
all nine invasive cancers were detected after 12.3 months 
with a median tumor size of 9 mm (range, 2–12 mm) and 
without lymph node metastasis. Two malignancies with 
progression after the initial BI-RADS 3 assessment at 12.4 
months and 21.2 months were 9-mm and 12-mm invasive 
cancers without lymph node metastasis. Therefore, in the 
screening center, a one-year follow-up might be cautiously 
recommended for BI-RADS 3 lesions. In the tertiary center, 
two invasive cancers were diagnosed at 6 months; one 
progressing from a BI-RADS 3 lesion was a 7-mm invasive 
cancer without axillary lymph node metastasis and the 
other was a new 16-mm invasive cancer with one axillary 
lymph node metastasis. In the tertiary center, more caution 
is needed and a 6-month-follow-up in the tertiary center 
may be appropriate. 
Our study has some limitations. First, it was a 
retrospective study and 495 of 1946 women were excluded. 
A selection bias might exist, and malignancy rates might 
be overestimated. However, the overestimation would not 
change our results. Second, data from screening breast 
US performed at a single tertiary center and its branch 
screening center were included. A multicenter study is 
needed to generalize our findings. Third, US examinations 
were performed by 16 radiologists and inter-observer 
variability might exist. Inter-observer variability was not 
analyzed in this study. However, the inclusion of many 
radiologists with differing levels of experience is reflective 
of routine daily practice. 
In conclusion, one-year follow-up rather than 6-month 
follow-up might be more appropriate for BI-RADS 3 lesions 
identified during screening US in screening centers. 
However, more caution is needed in tertiary centers where a 
6-month follow-up may be more appropriate.
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